

How I treat Parkinson's disease

Como eu trato a doença de Parkinson

Egberto Reis BARBOSA¹, João Carlos Papaterra LIMONGI¹, Hsin Fen CHIEN¹, Pedro Melo BARBOSA¹,
Marcela Reuter Carréra TORRES¹

ABSTRACT

Background: Parkinson's disease (PD) is a complex neurodegenerative condition. Treatment strategies through all stages of disease progression could affect quality of life and influence the development of future complications, making it crucial for the clinician to be on top of the literature. **Objective:** This paper reviews the current treatment of PD, from early to advanced stages. **Methods:** A literature review was conducted focusing on the treatment of PD, in the different stages of progression. **Results:** Every individual with a new diagnosis of PD should be encouraged to start exercising regularly. In the early stage, treatment should focus on using the lowest dose of levodopa or combination therapy that provides maximum functional capacity, and does not increase the risk of complications, such as peak dose dyskinesias and impulse control disorders. At the moderate and advanced stages, motor fluctuations and complications of treatment dominate the picture, making quality of life one important issue. Rehabilitation programs can improve motor symptoms and should be offered to all patients at any stage of disease progression. **Conclusion:** Many factors need to be considered when deciding on the best treatment strategy for PD, such as disease progression, presence of risk factors for motor and behavioral complications, potential side effects from dopaminergic therapy and phenotypical variabilities. Treatment should focus on functional capacity and quality of life throughout the whole disease course.

Keywords: Parkinson Disease; Therapeutics; Levodopa.

RESUMO

Antecedentes: A doença de Parkinson (DP) é uma doença neurodegenerativa complexa. As estratégias de tratamento ao longo de todos os estágios da evolução podem influenciar a qualidade de vida e o desenvolvimento de futuras complicações e, portanto, devem ser devidamente conhecidas pelos médicos que assistem o paciente. **Objetivo:** Neste artigo são revistos os tratamentos atuais para a DP, desde o estágio inicial até os estágios avançados. **Métodos:** Uma revisão da literatura foi realizada com enfoque em diferentes estágios da doença. **Resultados:** Todos os pacientes que recebem o diagnóstico de DP devem ser orientados a praticar atividades físicas regularmente. Em fase inicial do tratamento a estratégia consiste em usar doses mínimas de levodopa ou terapias combinadas que propiciem máxima capacidade funcional, que não aumentem o risco de complicações motoras, tais como discinesias induzidas por levodopa, ou não motoras, como transtornos do controle do impulso. Em estágio moderado ou avançado da doença, complicações como flutuações motoras e discinesias tornam-se relevantes e devem ser manejadas adequadamente. Programas de reabilitação devem ser oferecidos para os pacientes em todos os estágios da DP. **Conclusões:** Vários fatores devem ser considerados ao se escolher a melhor estratégia para o tratamento da DP. Entre eles destacam-se: fatores de risco para o desenvolvimento de complicações motoras e comportamentais, potenciais efeitos colaterais da terapia dopaminérgica e variabilidade fenotípica. O objetivo das estratégias de tratamento ao longo de toda a evolução da doença é a melhoria da capacidade funcional e da qualidade de vida dos pacientes.






Palavras-chave: Doença de Parkinson; Terapêutica; Levodopa.

INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. PD prevalence ranges from 102 to 190 per 100,000 in Western countries¹, affecting both

men and women, but being slightly more common in men. The disease typically develops after the age of fifty and may affect up to 2% of the population older than 65 years old². From 1900 to 2015 the projection of the number of people with PD doubled to over 6 million, mainly due to ageing population.

¹Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo SP, Brazil.

ERB  <https://orcid.org/0000-0002-6996-9130>; JCPL  <https://orcid.org/0000-0003-1684-0154>; HFC  <https://orcid.org/0000-0002-2490-6021>; PMB  <https://orcid.org/0000-0001-7220-1563>; MRCT  <https://orcid.org/0000-0003-3299-7493>

Correspondence: Egberto Reis Barbosa; Email: egbertob@8415.com.br.

Conflict of interest: There are no conflicts of interest to declare.

Authors' contributions: ERB: conception and organization of the manuscript and writing the topic Introduction; JCPL: writing the topic Management of Early PD, conception and reviewing the manuscript; HFC: writing the topic Parkinson Disease Rehabilitation and reviewing the manuscript; PMB: writing the topics Treatment of Advanced Parkinson's disease and the abstract; MRCT: writing the topic An Algorithm for the Treatment of Motor Symptoms of PD and Recent Guidelines for the Treatment of Parkinson's, conception of the figure 1 disease and organization of the references.

Received on March 21, 2022; Accepted on April 29, 2022.



The number of people affected is projected to a staggering 12.9 million people affected by 2,040³. Early-onset PD denotes disease onset below age 40, and juvenile PD when age of disease onset is below 21 years.

PD is a complex disorder with a broad spectrum of motor and non-motor features that require an individualized therapeutic approach. Several guidelines for the treatment of PD are available in the literature⁴. The main drugs used for the treatment of motor manifestations of the disease are: levodopa, dopamine agonists, catechol-o-methyltransferase inhibitors, monoamine oxidase inhibitors, amantadine and anticholinergics⁵.

LEVODOPA

Levodopa is the most effective drug for the treatment of symptoms of Parkinson disease. In the 1970s, it was discovered that adding a dopa decarboxylase inhibitor to levodopa to reduce its peripheral metabolism would lessen treatment side effects and show better symptom control. Levodopa treatment contributes to greater activity levels, independence, employability and consequently improved patient's quality of life⁶. Levodopa dose should be kept as low as possible to maintain good function in order to reduce the risk of motor complications.

For patients with prolonged off periods or severe dysphagia an encapsulated levodopa powder can be administered orally via an inhaler, but this preparation is not available in our country⁷.

Levodopa may lead to the development of longterm motor complications, including abnormal involuntary movements such as dyskinesias, dystonia, and response fluctuations.

The pathogenesis of motor complications associated with chronic levodopa therapy is still not fully understood. Theories include: presynaptic neuronal degeneration leading to insufficient buffering of released levodopa; postsynaptic changes in dopamine receptor number and its sensitivity, partially caused by presynaptic changes; and pharmacokinetic and pharmacodynamics changes of chronic dopaminergic therapy. Motor complications may be also related to the pulsatile use of levodopa, which leads to an imbalance of basal ganglia opioid concentrations and resetting of voltage gated channels in N-methyl-D-aspartate (NMDA) receptors^{8,9}.

Different levodopa formulations have been developed to provide more desirable delivery to avoid or prevent levodopa-related complications, but most of them are ineffective for these goals. A continuous intrajejunal infusion of levodopa-carbidopa intestinal gel has been found effective in smoothing out motor fluctuations⁵.

DOPAMINE AGONISTS

Dopamine agonists (DA) act directly stimulating dopamine brain receptors. There are two DA subclasses: ergoline and non-ergoline agonists. Ergoline dopamine agonists include bromocriptine, pergolide, lisuride, and cabergoline, whereas ropinirole, pramipexole and rotigotine (patch application) are

non-ergoline agonists. Apomorphine was the first DA shown to improve parkinsonian symptoms, but it has to be administered subcutaneously (not available in our country). Only non-ergot dopamine agonists, such as pramipexole and rotigotine, both available in Brazil, should be used because ergot agonists may cause pulmonary and cardiac fibrosis.

DA has been used as monotherapy in de novo patients with the intention of delaying levodopa treatment. DA are also used as adjunct to levodopa treatment in patients exhibiting motor fluctuation. DA rather than levodopa use appears to postpone onset of motor complications and dyskinesias, since motor complications may be related to the pulsatile use of levodopa as previously mentioned. DA display longer half-lives and differences in receptor selectivity, while dopaminergic therapy may lead to the development of Impulse control disorders, more common in patients on dopamine agonists therapy.

For patients with severe off periods and delayed onset with subsequent dosing, self-administered subcutaneous apomorphine injections (available outside Brazil) can be used to obtain a faster motor response.

CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMTI)

When peripheral decarboxylation is blocked by carbidopa or benserazide, the next metabolic pathway of levodopa is O-methylation by COMT. COMTIs block dopamine degrading enzymes, prolonging the benefits of levodopa by improving its bioavailability and inhibiting the formation of 3-O-methyldopa.

Entacapone (the only COMTI available in Brazil) inhibits COMT peripherally and tolcapone inhibits it both centrally and peripherally. Opicapone is a new generation once-daily administration COMTI, not yet available in Brazil. These drugs prolong the antiparkinsonian effect of levodopa and also allow levodopa dose reduction. Combination of COMT inhibitors and levodopa is indicated in patients with wearing off.

MONOAMINE OXIDASE INHIBITORS (MAOI)

Most of the MAO in the brain are type B and play an important role in the monoamine breakdown, such as dopamine. Three MAO inhibitors are available for the treatment of PD: selegiline, rasagiline and safinamide.

Although selegiline and rasagiline are most frequently used in early and mild PD, these MAOI are also effective in patients with moderately advanced PD with levodopa-related motor complications. A third generation of MAOI, safinamide, administered once daily (50–100 mg/day), has been found to increase patients' on time without troublesome dyskinesia and to reduce daily and morning off times¹⁰. Safinamide is a reversible MAOI, it also reduces neuronal dopamine reuptake and blocks voltage-dependent activated sodium channel and intracellular calcium entry, reducing neuronal glutamate release.

AMANTADINE

Amantadine, originally used as an antiviral drug, was fortuitously recognized to be a treatment for PD despite being a weak therapeutic agent. This drug increases dopamine release and blocks dopamine reuptake. Recent studies have demonstrated that amantadine is a weak NMDA glutamate receptor antagonist. Thus, amantadine can influence glutamatergic neurotransmission in corticostriatal synapses or at the subthalamic-internal pallidal synaptic level. Moreover, recent randomized clinical trials have also shown that amantadine reduces dyskinesias and motor fluctuations in patients receiving levodopa¹¹. Immediate-release amantadine is used off label for dyskinesia. Extended-release amantadine preparations was approved by the FDA for dyskinesia¹².

ANTICHOLINERGICS

The oldest class of medicines to treat PD is the anticholinergic (ACH) drugs. Biperiden and trihexyphenidyl reduce cholinergic activity contributing to reestablish the balance between striatal cholinergic and dopaminergic activity. The most recognized ACH drug use is to treat tremor in early or young onset PD, but ACH drugs do not significantly affect bradykinesia or rigidity. The most common side effects of ACH include dry mouth, blurred vision, constipation, and difficulty voiding the bladder. ACH can cause confusional states in elderly patients.

SURGICAL TREATMENT

Deep brain stimulation (DBS) of the subthalamic nucleus or internal globus pallidus are indicated to manage patients with severe dyskinesias and motor fluctuations. In the topic "Treatment of the advanced phase of PD" additional brief comments about this subject will be made. Details about the indications criteria and complications related to this procedure will be discussed in another article of this issue.

MODIFYING-DISEASE THERAPIES

Multiple lines of research point to several pathways which may contribute to neurodegeneration in PD: mitochondrial dysfunction, defective autophagy, abnormal protein accumulation of α -synuclein and synaptic impairment. Although effective therapies are available for the symptomatic control of PD treatments to halt the progression of the neurodegeneration process do not exist so far. Development of disease-modifying therapies to slow, mitigate or prevent PD is crucial, and new approaches to development of these agents have been proposed recently by Kiebert et al.¹³.

MANAGEMENT OF EARLY PD

Early stage PD begins when the first motor symptoms are noticed and the diagnosis is established. This stage may last for months or a few years, until symptoms begin to interfere with daily activities and quality of life is affected.

There are many treatment options to control symptoms in early stages of PD. Optimal management in individual patients depends on a number of variables such as age, cognitive status, symptom severity, predominance of bradykinesia or tremor, degree of dominant hand involvement, functional disability and employment status, among others. Medical treatment of early PD consists of dopamine replacing strategies to relieve motor symptoms, but eventually, other medical interventions may be required to treat nonmotor symptoms, such as depression or bowel constipation. No neuroprotective therapy is currently available to treat PD.

Four main classes of drugs are currently considered to be useful for initial PD: monoamine oxidase type B (MAO-B) inhibitors, amantadine, dopamine agonists (DA) and levodopa. Occasionally, anticholinergic drugs may be used in young patients with predominant tremor. These drugs have different pharmacological profiles, potencies and side effects. None of them has been found to be neuroprotective. MAO-B inhibitors and amantadine are less potent and can be used in patients with mild symptoms. Side effects are usually mild and well tolerated. DAs have a more potent dopaminergic effect and a longer half-life than levodopa. There is a lower risk of producing motor complications compared to levodopa, but adverse effects can be troublesome and include somnolence, hallucinations and impulse control disorders. Levodopa is the most effective drug and all patients will use this drug at some point in the course of the disease. However, short half-life and higher risk of development of dyskinesias are limitations to be considered^{14,15}.

Some clinicians have advocated that levodopa should be used as the initial therapy in spite of the known risk of producing motor fluctuations and dyskinesias¹⁶. The main argument is that there is no proof that levodopa is toxic to the brain or that the cause of motor complications is levodopa itself. In fact, there are reasons to indicate that dyskinesias correlate with disease severity and duration and not with duration of levodopa therapy. Moreover, it may be reasonable to argue that the most effective drug should be used in the early stages to provide the best quality of life from the start. Furthermore, the increasing recognition of severe impulse control disorders have cautioned against the use of DAs in more vulnerable patients¹⁷.

Moreover, those who prefer to delay the introduction of levodopa in favor of other dopamine-sparing drugs do not recommend postponing its use beyond the patient clinical requirement.

Two pivotal studies deserve mention regarding early levodopa treatment. The ELLDOPA study was a controlled

clinical trial aimed to evaluate the effect of levodopa on the clinical course of PD. Results showed that subjects treated with levodopa had less clinical progression after a two-week washout period compared to the placebo group, and that this effect was dose-dependent. In spite of some discordance between clinical results and ligand imaging findings suggesting increased degeneration in dopamine terminal neurons in the levodopa arms, the overall conclusion of this study was that levodopa is not toxic¹⁸.

The other trial was the LEAP study, which was a delayed-start clinical trial to investigate whether early treatment with levodopa had a beneficial disease modifying effect on PD. The results showed no differences between groups and the authors concluded that levodopa does not have a disease modifying effect¹⁹.

A recent report of the American Academy of Neurology reviewed the current evidence on the options available for initiating treatment of motor symptoms in early-stage PD. The main recommendations are summarized below²⁰.

Levodopa vs. DAs vs. MAO-B inhibitors

Clinical trials have failed to provide evidence of disease modifying effects when therapy is initiated with any class of drugs. Studies comparing treatment with levodopa with treatment with MAO-B inhibitors demonstrate greater improvement with levodopa and > 60% of individuals randomized to MAO-B inhibitors will require additional therapy within two to three years. (PD MED)²¹.

Initial treatment of early PD with levodopa provides greater benefit for motor symptoms, but is more likely to induce dyskinesias than initial treatment with DAs. Treatment with DAs may be more likely to cause more hallucinations compared with levodopa, but the difference is small for the first five years. Treatment with DAs in early PD carries a higher risk of impulse control disorders. Patient characteristics may provide clues to the risk of adverse effects. Younger age at onset, lower body weight, female gender and disease severity are predisposing factors for levodopa-induced dyskinesias. Predisposing factors for impulse control disorders are younger age, male gender and history of previous mood disorders. Cognitive and behavioral adverse effects are more common in older patients treated with DAs.

Overall recommendations regarding comparison studies among drugs are as follows:

- In patients who seek treatment for motor symptoms, levodopa should be the initial dopaminergic therapy;
- DAs may be prescribed as initial drug in patients < 60 years, who are at higher risk for dyskinesias;
- DAs should not be prescribed to patients older than 70 years, or with a history of impulse control disorders, cognitive impairment, daytime sleepiness or hallucinations.

Recommendations for levodopa

Studies comparing immediate-release, extended release or levodopa/carbidopa/entacapone formulations did not

detect significant differences. Recommendations for levodopa prescription are:

- Immediate-release should be preferred over extended release or association with entacapone formulations in patients with early PD;
- Lowest effective doses should be prescribed to minimize risk of adverse effects;
- Patients should be advised that higher dosages increase the risk of dyskinesias;
- Patients should be advised that taking levodopa with meals may decrease levodopa effect, but this is usually not a problem in early disease stages.

Recommendations for DAs

- Patients and caregivers should be informed of side effects of DAs, such as impulse control disorders, sudden-onset sleepiness, postural hypotension and hallucinations;
- Patients should be screened for the above symptoms and for cognitive impairment;
- There is no compelling evidence that pramipexole extended-release vs. pramipexole immediate-release was associated with more favorable UPDRS scores;
- There are preliminary reports that long-acting and transdermal formulations of DAs have lower rates of impulse control disorders than short-acting formulations;
- The lowest effective dose of DAs should be prescribed.

Recommendations for MAO-B inhibitors

- Most patients on monotherapy with a MAO-B inhibitor will require additional therapy after two to three years. This class of drug is associated with higher risk of adverse effects on discontinuation compared to levodopa treatment;
- There are no studies comparing the efficacy of selegiline, rasagiline and safinamide;
- Both drugs are superior to placebo for the treatment of motor symptoms;
- Although serotonin syndrome is rarely reported in PD, prescribing information cautions against concomitant use of MAO-B inhibitors and serotonin reuptake inhibitors.

TREATMENT OF ADVANCED PARKINSON'S DISEASE

Definition of advanced PD and its challenges

Advanced stage PD is defined by the presence of functional limitation despite optimized treatment, and occurrence of motor complications associated with dopamine replacement therapy (DRT), such as motor fluctuations, dyskinesias and psychosis. Postural instability and/or regular falls, gait freezing, postural

abnormalities (camptocormia, Pisa syndrome) and cognitive impairment are the main conditions associated with disability at this stage, negatively affecting quality of life of affected individuals. The term end stage PD is also used by some authors when there is significant disability and poor response to available treatments²². In the Hoehn and Yahr (H&Y) classification, advanced PD is classified as stages 4 or 5²³.

In the advanced stage of the disease most patients present with symptoms that are not improved by levodopa. Hely and colleagues showed that after 15 years of disease progression the main motor symptoms affecting individuals with PD are: motor complications of dopamine replacement treatment (dyskinesias and wearing-off), regular falls and choking. The main nonmotor symptoms (NMS) are cognitive decline, depression, hallucinations, urinary incontinence and postural hypotension²⁴. Periodic consultations with a movement disorders neurologist could help manage the complications of DRT and guide treatment decisions, particularly concerning advanced therapies, such as infusion therapies and surgical procedures²⁵.

Non-pharmacological treatment of advanced PD

Physical therapy and exercise can improve PD symptoms not usually ameliorated by DRT, such as gait impairment and freezing, postural instability, falls, and non-motor symptoms, such as depression, constipation, apathy, and fatigue²⁶. It is good practice to recommend physical exercise to all patients with a recent diagnosis of PD. Individuals with advanced PD, on the other hand, are at greater risk of injury from exercising and need a personalized approach. At this stage, physical therapy should focus on prevention of falls, improving transfers, posture, balance, and gait. This could be achieved by assisted active exercising and training of cognitive movement strategies. In patients with H&Y 5 physical therapy can help preventing contractures and pressure sores as well as help with postural adjustments²⁷. An occupational therapist could contribute to caregiver education, helping to reduce caregiver burden, to improve quality of care, and to advise environmental adaptations to reduce risk of falls and injuries²⁸.

Speech problems such as hypophonia and dysarthria frequently fail to improve with levodopa, and can worsen as the disease progresses, being a significant source of distress for individuals with PD, particularly in the advanced stage. Speech rehabilitation can improve dysarthria and possibly increase voice pitch, and should therefore be offered to any patient suffering from these symptoms²⁹. Dysphagia is a common symptom in advanced PD3 and should prompt referral to a speech therapist.

Pharmacological treatment of advanced PD

Motor complications of dopaminergic treatment

Motor fluctuations are the main complications of levodopa therapy in advanced PD. Motor fluctuations are predictable: end of dose (wearing-off), unpredictable: OFFs, ON-OFF

phenomenon, delayed-on and dose failures. Troublesome motor fluctuations affect 43% of patients with PD after five years of disease progression³⁰ and become more frequent with time, affecting approximately 80% of individuals 10 years after diagnosis. Motor fluctuations are associated with younger age at disease onset, longer disease duration and higher doses of levodopa^{31,32}. Unpredictable ON-OFF phenomenon usually occurs later in disease course³³.

Dyskinesias are involuntary movements that occur in an individual with PD showing a temporal relationship to levodopa ingestion³⁴. Dyskinesias are associated with longer disease duration, affecting 59% of individuals after 10 years of disease progression. Risk factors for development of levodopa-induced dyskinesias (LID) are younger age at PD onset, higher levodopa dose and presence of motor fluctuations³⁵.

Different types of dyskinesias are seen in PD. Dyskinesias that occur at peak levodopa serum concentration are the most common, these dyskinesias are choreiform, appear initially in the more affected body side, and do significantly impact on quality of life.1 Dystonia is commonly painful, can affect as many as 30% of individuals with PD, and is seen in OFF periods^{35,36}. Diphasic dyskinesias are rare, occur a few moments before levodopa kicks in and wears off, and are usually manifested as stereotyped movements of one or both legs²².

Treatment of motor complications

The likelihood of developing complications from dopamine replacement therapy is substantially increased in the advanced stage of PD. The treating physician faces complex choices in the trade-off between motor control and treatment adverse effects. Considering that levodopa is more effective and safer than the other dopaminergic drugs, it should be the preferred treatment for motor symptoms at this stage²⁵. Reinforcing the recommendation to take levodopa away from meals can help reduce delayed ONs. Soluble levodopa tablets, which are absorbed faster, are also useful to improve delayed ON³⁷. Reduction of OFF periods can be achieved by increasing levodopa dose or adding catechol-O-methyltransferase inhibitors (iCOMT), however both strategies can lead to supratherapeutic levels of levodopa, contributing to adverse effects and peak-dose dyskinesias^{25,38}.

Controlled release formulations of levodopa have longer bioavailability and could theoretically improve ON time, however it is still unclear whether these are helpful in controlling motor fluctuations. Night time rigidity and akinesia, on the other hand, could be improved by a bedtime dose of controlled release levodopa.16 Sudden OFF periods and morning akinesia could be improved by rescue apomorphine injections³⁹.

TREATMENT OF LEVODOPA-INDUCED DYSKINESIAS (LID)

Correct identification of the type of dyskinesias is of paramount importance for treatment success. Diphasic and dystonic

dyskinesias could be improved by increasing levodopa dosage, whereas peak-dose dyskinesias usually respond to a reduction in levodopa dose or the total amount of dopamine replacement therapy²⁵. When treating peak-dose dyskinesias it is important to consider that most patients are not bothered by the involuntary movements nor perceive any functional impairment related to peak dose dyskinesias. A reduction of levodopa dosage is not always necessary and could lead to motor deterioration⁴⁰.

When levodopa dose reduction with the goal of ameliorating dyskinesias results in inadequate motor control, add-on therapy, with dopamine agonists or MAOi, is usually recommended to patients in earlier stages of PD. However, due to potential side effects, these medications are not recommended for individuals with advanced disease. Controlled release levodopa has not been shown to be superior to standard release levodopa in controlling dyskinesias^{35,37}.

Amantadine is the only medication that acutely improves peak-dose dyskinesias without worsening motor symptoms. The initial dose is 100 mg daily, which can be increased up to 400 mg daily, depending on tolerability. In advanced PD amantadine should be used with caution, because of higher propensity to side effects, particularly visual hallucinations and executive dysfunction. In the presence of cognitive impairment, an alternative treatment should be sought³⁵.

Safinamide, a drug with dopaminergic and anti-glutamatergic properties appears to improve dyskinesias in a long-term scenario at a dose of 100 mg daily, but it appears to show no acute effect in reducing the severity of peak dose dyskinesias⁴¹. Clozapine, an atypical antipsychotic drug, can improve peak-dose dyskinesias. However, the need to monitor white blood cells count and cardiovascular risk makes it an unsuitable option for most patients³⁵.

INFUSION THERAPIES

Infusion therapies can deliver levodopa to the brain in a more constant way, bypassing the gastrointestinal tract and minimizing absorption rate variability. Potential benefits are reduction of OFF periods and adverse events associated with suprathreshold levels of levodopa, such as peak-dose dyskinesias, making these therapies suitable for individuals with advanced PD. Two types of infusion therapies are available, levodopa-carbidopa intestinal gel (LCIG) and apomorphine continuous infusion.

LCIG is administered continuously via a percutaneous endoscopic gastrostomy-jejunostomy feeding tube and has the inconvenience of relying on an infusion system³⁴. Apomorphine is a short-acting dopamine agonist with pharmacological properties akin to levodopa, with higher affinity for dopaminergic D1 and D2 receptors, that can also be administered via subcutaneous continuous infusion. Both LCIG and apomorphine infusion are effective in reducing OFF time in individuals with advanced PD and motor complications^{42,43} making them good therapeutic options for individuals who are not candidates for

deep brain stimulation. These drugs are safe for individuals with a present or past history of impulse control behaviours^{44,45}.

SURGERY

Many of the complications of advanced stage PD, such as postural instability, falls and cognitive impairment, make individuals at this stage of the disease unsuitable for deep brain stimulation (DBS)¹. In a recent systematic review, DBS was superior to best medical treatment and similar to LCIG in controlling motor symptoms of advanced PD. In suitable patients the decision to undergo DBS should be individualized, considering risks, potential benefits, costs and life expectancy⁴⁶. Lesioning procedures can also be considered if surgical risk permits. Pallidotomy, for instance, is effective in reducing levodopa-induced dyskinesias and OFF period disability^{47,48}.

TREATMENT OF NONMOTOR SYMPTOMS

Comprehensive treatment of nonmotor symptoms is beyond the scope of this section, which will focus on the NMS more frequently seen in advanced PD. NMS are a significant source of distress and have a negative impact on the quality of life of individuals with PD, particularly in advanced disease stages²². NMS can be a consequence of the disease or a complication of DRT. When NMS occurs in association with OFF symptoms (nonmotor OFF), NMS could be improved using the same strategies used to minimize motor OFF periods^{22,25}. The most common nonmotor OFF symptoms are pain, akathisia, depression, anxiety, dysphoria and dysautonomia²².

Considering that many NMS are worsened by DRT and/or difficult to distinguish from complications of treatment, individuals with advanced PD and significant NMS benefit from dose reduction and simplification of treatment regimen (favoring levodopa over other classes of medication). This is particularly true for individuals with psychosis or cognitive impairment²⁵. If cognitive impairment remains an issue in patients on levodopa monotherapy, the treating physician should attempt to establish the minimum levodopa dose necessary to control motor symptoms. Cholinesterase inhibitors could be prescribed, if motor deterioration prevents further reduction of levodopa in individuals with significant cognitive impairment. Rivastigmine and donepezil have both been shown to improve cognitive function and psychosis in PD⁴⁹. If psychosis in advanced PD fails to improve with the measures discussed above, antipsychotics can be prescribed. Quetiapine and clozapine are the only antipsychotics that do not worsen parkinsonian symptoms, and are both useful to treat psychosis and visual hallucinations²⁵.

Orthostatic hypotension is common in advanced PD. Reduction of levodopa and other contributing medication should be attempted, if possible, in addition to non-pharmacological measures, such as increased fluid and salt intake,

avoiding carbohydrate rich meals, and preferring smaller, more frequent meals. There is still no consensus guiding the decision to initiate pharmacological treatment. The drugs available to treat orthostatic hypotension are domperidone, fludrocortisone, droxidopa and midodrine⁵⁰.

Impulse control behaviors (ICB) mainly affect individuals with young onset PD, but a significant proportion of patients remain symptomatic in the long run⁵¹. Reduction of DRT and/or initiation of infusion therapies are treatment options for individuals with advanced PD and troublesome ICBs⁵².

PALLIATIVE CARE

Palliative care in PD focuses on improving quality of life and autonomy, planning advance care, and supporting caregivers. In advanced PD it should be seen as a complementary treatment strategy that could be used in parallel to other treatments. Decision to start palliation is difficult considering the variability in clinical phenotypes. Generally, limited lifetime expectancy, rapid disease progression, malnutrition, impaired breathing, or the occurrence of life-threatening complications in the previous year are clues that could be used to identify individuals who would benefit from palliative care. Palliative care can also be indicated with the prescription of a new intervention or when end of life is approaching⁵³.

PARKINSON DISEASE REHABILITATION

Although pharmaceutical treatments improve PD manifestations, optimal management requires a multidisciplinary approach. Independently of the stage of the disease, patients and caregivers may benefit from tailored rehabilitation programs according to their needs⁵⁴. Many rehabilitation interventions have been proven to improve PD symptoms⁵⁵ and clinical practice guidelines have been published to help therapists and neurologists to provide best decision making for the management of PD patients treatment⁵⁶.

A recent meta-analysis evaluated the effect of different physical therapy (PT) interventions on motor symptoms, balance, gait and quality of life (QoL)⁵⁷. The authors concluded that conventional PT improved motor symptoms, gait, and QoL. Resistance and treadmill training improved gait, hydrotherapy improved balance, and strategy training improved balance and gait. Dance, Nordic walking, martial arts, and balance and gait training improved motor symptoms, balance, and gait. Dual task training (DT) did not improve motor symptoms, balance, gait and QoL. Although this last finding might seem conflicting with proven benefits of DT^{55,58,59}, DTT should be implemented in PD rehabilitation, because of the motor learning principle⁶⁰. Patients improve mobility and cognitive function when both motor and cognitive activities are

integrated during DT training⁵⁵. Caution should be taken with people with higher falling risk, freezing of gait or mild cognitive impairment. Good strategies and tailoring exercises to each patient's personal and physical cognitive abilities⁶¹ may reduce or avoid risks during training.

Many studies suggest that aerobic and high intensity exercises may attenuate PD symptoms⁶². Resistance training improves muscle strength, mobility, balance, functional capacity, QoL and reduces the risk of falls of PD patients⁶³. Exercise may improve cognitive functions of PD patients at a mild to moderate stage of the disease⁶⁴. Exergaming and virtual reality training can be useful to improve gait in PD⁶⁵. Whether these effects are merely symptomatic or reflective of a possible disease-modifying effect requires further study⁶⁶. Overall, there are long-term effects with exercise training⁶⁷ but there is no consensus about which types of exercises are better for PD, and, therefore, individualized prescription, similarly to pharmacotherapeutic interventions, such as frequency, duration, and intensity, is required⁶⁸.

Recent meta-analysis demonstrated the efficacy of the Lee Silverman Voice Treatment in increasing vocal loudness and functional communication among individuals with PD⁶⁹. Speech language therapy (SLT) has potential benefits for PD dysphagia⁷⁰. Intensive SLT is effective for hypophonia and can lead to some improvement of voice pitch but behavioral speech rehabilitation in PD still needs validation⁷¹.

Although occupational therapy (OT) has a perceived possibly beneficial role for PD, studies about the effect of OT in PD are scarce. In 2014, Sturkenboom et al.⁷² demonstrated that OT can improve the self-perceived performance of PD patients in daily activities. Different OT interventions may be effective in improving QoL in patients with PD. Because of the lack of high-quality studies, further investigations are needed to establish firm conclusions about OT efficacy in PD⁷³.

AN ALGORITHM FOR THE TREATMENT OF MOTOR SYMPTOMS OF PD AND RECENT GUIDELINES FOR THE TREATMENT OF PARKINSON'S DISEASE

Based on this review, we propose an algorithm as a guide for the treatment of motor symptoms in PD (Figure 1). Moreover, it is important to mention three recently published guidelines with recommendations concerning the treatment of PD: the Canadian guideline⁴, the Brazilian guideline of the Movement Disorders Scientific Department of the Brazilian Academy of Neurology⁷⁴ and the American Academy of Neurology guideline²⁰. They review the current evidence of available treatment options for PD. Additionally, an update on the management of PD for general neurologists was recently published by Pyrtosek et al⁷⁶. These written materials can help doctors to improve treatment strategies for PD patients.




Figure 1. Treatment of PD motor symptoms.

References

- Schrag A. Epidemiology of movement disorders. In: Jankovic J, Tolosa E. Parkinson's disease and movement disorders. Baltimore (MD): Lippincott; 2007 p. 50-2.
- Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. *Nat Rev Dis Primers*. 2017 Mar 23;3:17013. <https://doi.org/10.1038/nrdp.2017.13>
- Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. *J Parkinsons Dis*. 2018 Dec 18;8(s1):S3-8. <https://doi.org/10.3233/JPD-181474>
- Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, et al. Canadian guideline for Parkinson disease. *CMAJ*. 2019 Sep 9;191(36):E989-1004. <https://doi.org/10.1503/cmaj.181504>
- Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. *J Neurol Neurosurg Psychiatry*. 2020 Aug;91(8):795-808. <https://doi.org/10.1136/jnnp-2019-322338>
- Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. *Parkinsonism Relat Disord*. 2001 Oct 1;8(2):P95-100. [https://doi.org/10.1016/S1353-8020\(01\)00023-2](https://doi.org/10.1016/S1353-8020(01)00023-2)
- LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Neurol*. 2019 Feb 1;18(2):P145-54. [https://doi.org/10.1016/S1474-4422\(18\)30405-8](https://doi.org/10.1016/S1474-4422(18)30405-8)
- Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. *Neurology*. 2002 Aug 13;59(3):408-13. <https://doi.org/10.1212/wnl.59.3.408>
- Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. *Parkinson Study group*. *JAMA*. 2000 Oct 18;284(15):1931-8. <https://doi.org/10.1001/jama.284.15.1931>
- Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. *JAMA Neurol*. 2017 Feb 1;74(2):216-24. <https://doi.org/10.1001/jamaneurol.2016.4467>
- Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. *Neurology*. 2009 May 26;72(21 Suppl 4):S1-136. <https://doi.org/10.1212/WNL.0b013e3181a1d44c>
- Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. *JAMA Neurol*. 2017 Aug 1;74(8):941-9. <https://doi.org/10.1001/jamaneurol.2017.0943>
- Kiebertz K, Katz R, McGarry A, Olanow CW. A new approach to the development of disease-modifying therapies for PD; Fighting another pandemic. *Mov Disord*. 2021 Jan;36(1):59-63. <https://doi.org/10.1002/mds.28310>
- Hauser RA, Schapira AHV, Rascol O, Barone P, Mizuno Y, Salin L, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. *Mov Disord*. 2010 Nov 15;25(15):2542-9. <https://doi.org/10.1002/mds.23317>
- Latt MD, Lewis S, Zekry O, Fung VSC. Factors to consider in the selection of dopamine agonists for older persons with Parkinson's disease. *Drugs Aging*. 2019 Mar 8;36(3):189-202. <https://doi.org/10.1007/s40266-018-0629-0>
- Olanow WC, Kiebertz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. *Mov Disord*. 2013 Jul;28(8):1064-71. <https://doi.org/10.1002/mds.25364>
- Corvol J-C, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. *Neurology*. 2018 Jul 17;91(3):e189-201. <https://doi.org/10.1212/WNL.0000000000005816>
- Fahn S, Oakes D, Shoulson I, Kiebertz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. *N Engl J Med*. 2004 Dec 9;351(24):2498-508. <https://doi.org/10.1056/NEJMoa033447>
- Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized delayed-start trial of levodopa in Parkinson's disease. *N Engl J Med*. 2019 Jan 24;380(4):315-24. <https://doi.org/10.1056/NEJMoa1809983>
- Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. *Neurology*. 2021 Nov 16;97(20):942-57. <https://doi.org/10.1212/WNL.0000000000012868>
- PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. *Lancet*. 2014 Sep 27;384(9949):1196-205. [https://doi.org/10.1016/S0140-6736\(14\)60683-8](https://doi.org/10.1016/S0140-6736(14)60683-8)
- Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. Elsevier Saunders; 2011.
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. *Neurology*. 1967 May 1;17(5):427-42. <https://doi.org/10.1212/WNL.17.5.427>
- Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. *Mov Disord*. 2005 Feb;20(2):190-9. <https://doi.org/10.1002/mds.20324>
- Hwang H, Norris SA. Managing advanced Parkinson disease. *J Geriatr Psychiatry Neurol*. 2021 Jul 5;34(4):289-300. <https://doi.org/10.1177/08919887211018277>
- van der Kolk NM, King LA. Effects of exercise on mobility in people with Parkinson's disease. *Mov Disord*. 2013 Sep 15;28(11):1587-96. <https://doi.org/10.1002/mds.25658>
- Keus SHJ, Bloem BR, Hendriks EJM, Bredero-Cohen AB, Munneke M; Practice Recommendations Development Group. Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research. *Mov Disord*. 2007 Mar 15;22(4):451-60. <https://doi.org/10.1002/mds.21244>
- Foster ER, Bedekar M, Tickle-Degnen L. Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson's disease. *Am J Occup Ther*. 2014 Jan-Feb;68(1):39-49. <https://doi.org/10.5014/ajot.2014.008706>
- Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature. *Neurodegener Dis Manag*. 2015 Jun 24;5(3):233-48. <https://doi.org/10.2217/nmt.15.16>
- Olanow CW. The scientific basis for the current treatment of Parkinson's disease. *Annu Rev Med*. 2004 Feb 18;55:41-60. <https://doi.org/10.1146/annurev.med.55.091902.104422>
- Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. *Brain*. 2000 Nov 1;123(11):2297-305. <https://doi.org/10.1093/brain/123.11.2297>
- Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinicopathological study. *Brain*. 2007 Aug;130(8):2123-8. <https://doi.org/10.1093/brain/awm142>

33. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. *Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine*. *Neurology*. 1974 May 1;24(5):431-41. <https://doi.org/10.1212/WNL.24.5.431>
34. Moore H, Shpiner DS, Luca CC. Management of motor features in advanced Parkinson disease. *Clin Geriatr Med*. 2020 Feb 1;36(1):P43-52. <https://doi.org/10.1016/j.cger.2019.09.010>
35. Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. *Curr Neurol Neurosci Rep*. 2007 Jul;7(4):302-10. <https://doi.org/10.1007/s11910-007-0046-y>
36. Shetty AS, Bhatia KP, Lang AE. Dystonia and Parkinson's disease: what is the relationship? *Neurobiol Dis*. 2019 Dec;132:104462. <https://doi.org/10.1016/j.nbd.2019.05.001>
37. Fabbrini G, Di Stasio F, Bloise M, Berardelli A. Soluble and controlled-release preparations of levodopa: do we really need them? *J Neurol*. 2010 Nov;257(Suppl 2):292-7. <https://doi.org/10.1007/s00415-010-5734-x>
38. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. *Ann Neurol*. 2010 Jul;68(1):18-27. <https://doi.org/10.1002/ana.22060>
39. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1990 Feb 1;53(2):96-101. <https://doi.org/10.1136/jnnp.53.2.96>
40. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G; Parkinson Study Group. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. *Mov Disord*. 2004 Jan 6;19(1):22-8. <https://doi.org/10.1002/mds.10642>
41. Abbruzzese G, Barone P, Lopiano L, Stocchi F. The current evidence for the use of safinamide for the treatment of Parkinson's disease. *Drug Des Devel Ther*. 2021 Jun 10;15:2507-17. <https://doi.org/10.2147/DDDT.S302673>
42. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *Lancet Neurol*. 2014 Feb 1;13(2):P141-9. [https://doi.org/10.1016/S1474-4422\(13\)70293-X](https://doi.org/10.1016/S1474-4422(13)70293-X)
43. Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Neurol*. 2018 Sep 1;17(9):P749-59. [https://doi.org/10.1016/S1474-4422\(18\)30239-4](https://doi.org/10.1016/S1474-4422(18)30239-4)
44. Catalán MJ, Pablo-Fernández E, Villanueva C, Fernández-Diez S, Lapeña-Montero T, García-Ramos R, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. *Mov Disord*. 2013 Dec;28(14):2007-10. <https://doi.org/10.1002/mds.25636>
45. Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson's disease patients treated with continuous waking day apomorphine pumps. *Mov Disord Clin Pract*. 2016 Aug 11;4(3):323-28. <https://doi.org/10.1002/mdc3.12416>
46. Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson's disease advanced therapies - a systematic review: more unanswered questions than guidance. *Parkinsonism Relat Disord*. 2021 Feb 1;83:P132-9. <https://doi.org/10.1016/j.parkreldis.2020.10.042>
47. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. *N Engl J Med*. 1997 Oct 9;337(15):1036-42. <https://doi.org/10.1056/NEJM199710093371503>
48. Lai EC, Jankovic J, Krauss JK, Ondo WG, Grossman RG. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. *Neurology*. 2000 Oct 24;55(8):1218-22. <https://doi.org/10.1212/wnl.55.8.1218>
49. Watts KE, Storr NJ, Barr PG, Rajkumar AP. Systematic review of pharmacological interventions for people with Lewy body dementia. *Aging Ment Health*. 2022 Feb 2:1-14. <https://doi.org/10.1080/13607863.2022.2032601>
50. Fanciulli A, Leys F, Falup-Pecurariu C, Thijs R, Wenning GK. Management of orthostatic hypotension in Parkinson's disease. *J Parkinsons Dis*. 2020 Sep 1;10(s1):S57-64. <https://doi.org/10.3233/JPD-202036>
51. Barbosa PM, Djamshidian A, O'Sullivan SS, Pablo-Fernandez E, Korlipara P, Morris HR, et al. The long-term outcome of impulsive compulsive behaviours in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2019 Nov;90(11):1288-9. <https://doi.org/10.1136/jnnp-2018-319891>
52. Averbeck BB, O'Sullivan SS, Djamshidian A. Impulsive and compulsive behaviors in Parkinson's disease. *Annu Rev Clin Psychol*. 2014 Mar;10:553-80. <https://doi.org/10.1146/annurev-clinpsy-032813-153705>
53. Ng JSC. Palliative care for Parkinson's disease. *Ann Palliat Med*. 2018 Jul;7(3):296-303. <https://doi.org/10.21037/apm.2017.12.02>
54. Chien HF, Barbosa ER, Souza CO, Dias AE, Conti J. Parkinson's Disease. In: Chien HF, Barsottini OGP, editors. *Movement disorders rehabilitation*. Switzerland (CH): Springer; 2017. p. 5-43.
55. Barbosa AF, Chen J, Freitag F, Valente D, Souza CO, Voos MC, et al; Gait, posture and cognition in Parkinson's disease. *Dement Neuropsychol*. 2016 Oct-Dec;10(4):280-6. <https://doi.org/10.1590/s1980-5764-2016dn1004005>
56. Osborne JA, Botkin R, Colon-Semenza C, DeAngelis TR, Gallardo OG, Kosakowski H, et al. Physical therapist management of Parkinson disease: a clinical practice guideline from the American Physical Therapy Association. *Phys Ther*. 2022 Apr 1;102(4):pzab302. <https://doi.org/10.1093/ptj/pzab302>
57. Radder DLM, Lima ALS, Domingos J, Keus SHJ, van Nimwegen M, Bloem BR, et al. Physiotherapy in Parkinson's disease: a meta-analysis of present treatment modalities. *Neurorehabil Neural Repair*. 2020 Oct 1;34(10):871-80. <https://doi.org/10.1177/1545968320952799>
58. Freitas TB, Leite PHW, Doná F, Pompeu JE, Swarowsky A, Torriani-Pasin C. The effects of dual task gait and balance training in Parkinson's disease: a systematic review. *Physiother Theory Pract*. 2020 Oct;36(10):1088-96. <https://doi.org/10.1080/09593985.2018.1551455>
59. Freitag F, Brucki SMD, Barbosa AF, Chen J, Souza CO, Valente DF, et al. Is virtual reality beneficial for dual-task gait training in patients with Parkinson's disease? A systematic review. *Dement Neuropsychol*. 2019 Jul-Sep;13(3):259-67. <https://doi.org/10.1590/1980-57642018dn13-030002>
60. Strouwen C, Molenaar EALM, Münks L, Keus SHJ, Bloem BR, Rochester L, et al. Dual tasking in Parkinson's disease: should we train hazardous behavior? *Expert Rev Neurother*. 2015 Aug 7;15(9):1031-9. <https://doi.org/10.1586/14737175.2015.1077116>
61. Domingos J, Dean J, Fernandes JB, Godinho C. Professionals' self-reported difficulties towards integrating dual task training in care for people with Parkinson's disease. *Int J Environ Res Public Health*. 2022 Jan 24;19(3):1281. <https://doi.org/10.3390/ijerph19031281>
62. Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial. *JAMA Neurol*. 2018 Feb 1;75(2):219-26. <https://doi.org/10.1001/jamaneurol.2017.3517>

63. Chen J, Chien HF, Francato DCV, Barbosa AF, Souza CO, Voos MC, et al. Effects of resistance training on postural control in Parkinson's disease: a randomized controlled trial. *Arq Neuropsiquiatr*. 2021 Jul 5;79(6):511-20. <https://doi.org/10.1590/0004-282X-ANP-2020-0285>
64. Silva FC, Iop RDR, Oliveira LC, Boll AM, Alvarenga JGS, Gutierrez Filho PJB, et al. Effects of physical exercise programs on cognitive function in Parkinson's disease patients: a systematic review of randomized controlled trials of the last 10 years. *PLoS One*. 2018 Feb 27;13(2):e0193113. <https://doi.org/10.1371/journal.pone.0193113>
65. Pompeu JE, Mendes FA, Silva KG, Lobo AM, Oliveira TP, Zomignani AP, et al. Effect of Nintendo WiiTM-based motor and cognitive training on activities of daily living in patients with Parkinson's disease: a randomised clinical trial. *Physiotherapy*. 2012 Sep 1;98(3):P196-204. <https://doi.org/10.1016/j.physio.2012.06.004>
66. Ferrazzoli D, Ortelli P, Iansek R, Volpe D. Rehabilitation in movement disorders: from basic mechanisms to clinical strategies. *Handb Clin Neurol*. 2022;184:341-55. <https://doi.org/10.1016/B978-0-12-819410-2.00019-9>
67. Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. *Nat Rev Neurol*. 2017 Nov;13(11):689-703. <https://doi.org/10.1038/nrneurol.2017.128>
68. Bouça-Machado R, Rosário A, Caldeira D, Caldas AC, Guerreiro D, Venturelli M, et al. Physical activity, exercise, and physiotherapy in Parkinson's disease: defining the concepts. *Mov Disord Clin Pract*. 2019 Nov 11;7(1):7-15. <https://doi.org/10.1002/mdc3.12849>
69. Pu T, Huang M, Kong X, Wang M, Chen X, Feng X, et al. Lee Silverman voice treatment to improve speech in Parkinson's disease: a systematic review and meta-analysis. *Parkinsons Dis*. 2021 Dec 27;2021:3366870. <https://doi.org/10.1155/2021/3366870>
70. Gandhi P, Steele CM. Effectiveness of interventions for dysphagia in Parkinson disease: a systematic review. *Am J Speech Lang Pathol*. 2022 Jan 18;31(1):463-85. https://doi.org/10.1044/2021_AJSLP-21-00145
71. Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature. *Neurodegener Dis Manag*. 2015 Jun 24;5(3):233-48. <https://doi.org/10.2217/nmt.15.16>
72. Sturkenboom IHWM, Graff MJL, Hendriks JCM, Veenhuizen Y, Munneke M, Bloem BR, et al. Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. *Lancet Neurol*. 2014 Jun 1;13(6):P557-66. [https://doi.org/10.1016/S1474-4422\(14\)70055-9](https://doi.org/10.1016/S1474-4422(14)70055-9)
73. Tofani M, Ranieri A, Fabbrini G, Berardi A, Pelosin E, Valente D, et al. Efficacy of occupational therapy interventions on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis. *Mov Disord Clin Pract*. 2020 Oct 2;7(8):891-901. <https://doi.org/10.1002/mdc3.13089>
74. Saba RA, Maia DP, Cardoso FEC, Borges V, Andrade LAF, Ferraz HB, et al. Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms. *Arq Neuropsiquiatr*. 2021 Mar;80(3):316-29. <https://doi.org/10.1590/0004-282X-ANP-2021-0219>
75. Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. *Neurology*. 2021 Nov 16;97(20):942-57. <https://doi.org/10.1212/WNL.00000000000012868>
76. Pirtošek Z, Bajenaru O, Kovács N, Milanov I, Relja M, Skorvanek M. Update on the management of Parkinson's disease for general neurologists. *Parkinsons Dis*. 2020 Mar 26;2020:9131474. <https://doi.org/10.1155/2020/9131474>